Azitra presents preclinical data from ATR-04 trial

Azitra announced preclinical data from the company’s platform and pipeline. The data are being presented on Friday, May 17, in two oral sessions entitled “Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor inhibitor-induced dermal toxicity” and “Cutaneous delivery of LEKTI via an engineered strain of Staphylococcus epidermidis for the treatment of Netherton syndrome” at the Society of Investigative Dermatology 2024 Annual Meeting in Dallas. The data in the oral presentations showcase the preclinical development of ATR-04. ATR-04 led to a decrease in S. aureus across multiple models. In in vitro skin models, ATR-04 treatment led to a 96% reduction in methicillin-resistant S. aureus compared to untreated skin. In ex vivo pig skin treated with ATR-04, there was a 99% reduction in MRSA compared to untreated skin. Additionally, in human skin models treated with erlotinib, an EGFRi, ATR-04 reduced IL-36gamma by 75% to levels comparable to untreated skin models. Finally, ATR-04 increased human beta defensin, a key protein involved in host defenses, by 18-fold compared to vehicle. Together, the data show that ATR-04 can address multiple drivers of EGFRi-induced skin toxicity.